Ones To Watch News
Refine Search
Biotechnology
Privately-held French biotech StromaCare, which is developing immunotherapies through stroma modulation, today announced the appointment of Georges Rawadi as chief executive (CEO). 13 February 2024
Pharmaceutical
Foghorn Therapeutics has announced that its partner, Eli Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. 12 February 2024
Biotechnology
Sana Biotechnology has announced it has raised $165 million in a public offering, with Morgan Stanley, JP Morgan and Goldman Sachs acting as joint book-running managers. 12 February 2024
Pharmaceutical
CymaBay Therapeutics’ shares surged 24.5% to $31.99 pre-market, on the news of an acquisition bid from US major Gilead Sciences. 12 February 2024
Biotechnology
Immuno-dermatology company Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by healthcare-focused investment firm Medicxi. 12 February 2024
Biotechnology
USA-based clinical-stage biotech Mineralys Therapeutics has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of about $120 million 12 February 2024
Pharmaceutical
UK-based Poolbeg Pharma has announced that research conducted on its behalf confirms a market opportunity of at least $10 billon for POLB 001 in cancer immunotherapy-induced cytokine release syndrome (CRS) as an orally-delivered preventative therapy. 12 February 2024
Biotechnology
French hearing loss specialist Sensorion has raised 50.5 million euros ($55 million), offering new shares at a price of 0.57 euro cents per share. 9 February 2024
Biotechnology
US biopharma Synlogic is to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac in phenylketonuria (PKU), with the firm’s board now evaluating strategic options for the company. 9 February 2024
Biotechnology
Germany-based Vivoryon Therapeutics could well be on the path towards altering the course of Alzheimer’s disease (AD), with a PhII data readout coming up and an option offering potential advantages over recently-approved monoclonal antibodies (mAbs). 9 February 2024
Pharmaceutical
Vicor Pharma has entered into an exclusive licensing agreement with Japan’s Nippon Shinyaku, for the commercialization and development of its C21 idiopathic pulmonary fibrosis (IPF) drug candidate in Japan. 9 February 2024
Biotechnology
Regenerative cell therapy specialist Neurona Therapeutics has raised $120 million in a financing round co-led by Viking Global Investors and Cormorant Asset Management. 9 February 2024
Biotechnology
Swedish immuno-oncology company Alligator Bioscience saw its shares close up 2.4% at 1.13 kronor yesterday, after it announced plans to adjust the size of its organization. 9 February 2024
Biotechnology
German biotech BioNTech and USA-based Autolus Therapeutics today announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations. 8 February 2024
Biotechnology
Immuno-oncology firm I-Mab saw its shares slip 4.5% to $1.91 pre-market today, as it announced that, as part of its strategy to become a USA-based biotech, it is divesting its Chinese subsidiaries. 8 February 2024
Biotechnology
China-based Hutchmed has reported data from FRUTIGA, its Phase III trial of fruquintinib alongside paclitaxel for the treatment of second-line advanced gastric cancer in China, at the American Society of Clinical Oncology (ASCO) Plenary Series Session. 8 February 2024
Biotechnology
Shares of French ophthalmology biotech Nicox shot up 16.8% to 0.48 euros this morning, after it announced a deal with privately-held Japanese firm Kowa Company. 8 February 2024
Biotechnology
Hong Kong-listed biotech BeiGene has received Health Canada authorization for Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL). 8 February 2024
Biotechnology
California, USA-based biotech BridgeBio Pharma today announced a partnership wherein its affiliate, QED Therapeutics, grants Japan’s Kyowa Kirin an exclusive license for infigratinib. 7 February 2024
Biotechnology
The UK's Medicines and Healthcare Regulatory Agency (MHRA) has licensed subcutaneous (SC) injectable Vyvgart (efgartigimod alfa) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. 7 February 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze